Table 4.

Characteristics of discussed studies of rituximab in IgAN

Study	Study design	Population	Rituximab protocol	Selected outcomes	Results
Chancharoenthana et al31	Case series	Three kidney transplant patients and recurrence of IgAN	4 monthly doses at 375 mg/m2	Effect on proteinuria	Mean decrease of proteinuria of 3.1 g/day at month 6
		Proteinuria ranged between 3.4 and 5.5 g/day		Adverse events	No treatment-related adverse events at 12 months
Sugiura et al32	Prospective, single-arm trial	24 patients with primary glomerular disease	Single dose of 375 mg/m2	Proteinuria at 6 months	No change in patients with IgAN: 1±8 g/day at baseline vs 0.9±0.8 g/day at 6 months
		Included five patients with IgAN (proteinuria 1±0.8 g/day at baseline)		Adverse events	One patient had transient infusion-related reaction
Fernando Fervenza (ongoing trial)33	Prospective, multicenter, randomized controlled trial	54 patients with IgAN and proteinuria of >1 g/day	1 g, on days 1, 15, 168, and 182, vs placebo	Change in proteinuria and kidney function at 12 months	Pending

Abbreviation: IgAN, immunoglobulin A nephropathy.